Article3 Biotech2026
Combining network pharmacology and experimental validation to explore the therapeutic mechanism of Banxia Xiexin decoction in type 2 diabetes mellitus.
Article in 3 Biotech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance (IR), with chronic low-grade inflammation, oxidative stress, and mitochondrial dysfunction contributing to disease progression. Banxia Xiexin Decoction (BXXD), a classical traditional Chinese medicine (TCM) formula, has shown clinical efficacy against T2DM, but its bioactive components and molecular mechanisms remain unclear. This study aimed to elucidate the therapeutic mechanism of BXXD against T2DM by integrating network pharmacology, genetic causal inference, chemical profiling, and in vivo validation.Network pharmacology identified BXXD-T2DM overlapping targets and enriched pathways. Summary-data-based Mendelian randomization (SMR) and molecular docking assessed causality and binding affinity. Bioactive constituents were characterized by UHPLC-Q-Orbitrap HRMS. Mechanisms were validated in high-fat diet/streptozotocin (HFD/STZ)-induced diabetic C57BL/6J mice treated with BXXD for 8 weeks.Network pharmacology identified 217 targets, highlighting IL-1β, TNF-α, AKT1, PPARG, and SIRT1, with AMPK signaling highly enriched. SMR indicated that Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13205-026-05001-9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.